SCHEMBL13266244

SCHEMBL13266244

CCCC(C)(Cl)c1ccc(C(=O)c2ccc(Oc3ccc(OC(C)(CC)c4ccc(C(=O)c5ccc(Cl)cc5)cc4)c4ccccc34)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.39
▸ PPARA Q07869 5/20 0.38
▸ PPARG P37231 4/20 0.38
▸ FABP2 P12104 1/20 0.38
▸ SLC22A12 Q96S37 1/20 0.38
▸ MCL1 Q07820 2/20 0.37
▸ ELANE P08246 2/20 0.37
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ HPGD P15428 2/20 0.35
▸ LMNA P02545 2/20 0.35
▸ USP2 O75604 1/20 0.35
▸ ABCB11 O95342 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ ADRB3 P13945 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ CNR1 P21554 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13266248 0.92 PPARA (0.40) MAPTPPARAPPARGFABP2SLC22A12
SCHEMBL13602273 0.87 MCL1 (0.35) MAPTMCL1KMT2ASMN1; SMN2TDP1
SCHEMBL13266249 0.83 MCL1 (0.35) MAPTMCL1MEN1KMT2ACYP3A4
SCHEMBL13082580 0.83 MCL1 (0.40) MAPTPPARAMCL1ELANEKMT2A
SCHEMBL13082664 0.82 PPARA (0.40) MAPTPPARAPPARGFABP2SLC22A12
SCHEMBL13602275 0.80 MCL1 (0.35) MAPTPPARAMCL1KMT2AHPGD
SCHEMBL13082581 0.79 MCL1 (0.40) MAPTMCL1ELANEMEN1KMT2A
SCHEMBL822859 0.75 MAPT (0.57) MAPTPPARAPPARGFABP2SLC22A12
SCHEMBL13266188 0.75 MCL1 (0.39) MAPTMCL1ELANEMEN1KMT2A
SCHEMBL10227054 0.74 PPARA (0.43) MAPTPPARAPPARGFABP2SLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293905-B2 Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-23 — — US disclosed
US-20100184978-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-07-22 — — US disclosed
US-20090326188-A1 Method for producing polyarylene SUMITOMO CHEMICAL COMPANY, LIMITED 2009-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184978-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX C9, C5, AP2M1 MAPT 1124/4885PPARA 4231/4885PPARG 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback